Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
Calcineurin Inhibitors
/ administration & dosage
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Glomerular Filtration Rate
/ physiology
Graft Rejection
/ drug therapy
Graft Survival
/ drug effects
Humans
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ therapeutic use
Kidney
/ physiopathology
Liver Transplantation
Male
Middle Aged
Prognosis
Retrospective Studies
Sirolimus
/ therapeutic use
Time Factors
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
3
10
2019
medline:
8
10
2020
entrez:
3
10
2019
Statut:
ppublish
Résumé
The long-term use of calcineurin inhibitors (CNIs) after liver transplantation (LT) is associated with nephrotoxicity. Five-year follow-up data were retrieved from the randomized controlled multicenter SiLVER trial. Standard CNI-based mammalian target of rapamycin-free immunosuppression (group A, n = 264) was compared with a 50% reduction of CNI and introduction of the mammalian target of rapamycin inhibitor Sirolimus (SIR) within 4-6 weeks after LT (group B, n = 261). Median MELD at LT was low with 10 (7-15) (group A) and 11 (8-15) (group B) in the intention-to-treat approach. CNI dose and CNI trough were reduced by 20% and 8% (group A) versus 55% and 56% (group B) at 3 months posttransplantation. Renal function was preserved at 3 months after LT in the SIR arm (estimated glomerular filtration rate 74 [57-95] versus 67 [55-85] mL/min/1.73m2 P = 0.004) but was similarly impaired thereafter compared with group A. The per protocol analysis identified LT recipients in group B with concomitant early CNI minimization and SIR treatment ≥ year 1 with significantly superior estimated glomerular filtration rate and lowest rate of chronic kidney disease (≥stage 3) from year 1 onwards until study end. Competing risk factors for renal disease (arterial hypertension, fat metabolism disorder, and hyperglycemia) were not associated with worse kidney function. Prevention of CNI nephrotoxicity by SIR-based early CNI minimization protects renal function only short-term after LT in the intention-to-treat analysis of this low MELD cohort. Yet, selected LT recipients compliant with early CNI minimization and SIR maintenance achieved better long-term renal outcomes compared with real-world practice.
Sections du résumé
BACKGROUND
The long-term use of calcineurin inhibitors (CNIs) after liver transplantation (LT) is associated with nephrotoxicity.
METHODS
Five-year follow-up data were retrieved from the randomized controlled multicenter SiLVER trial. Standard CNI-based mammalian target of rapamycin-free immunosuppression (group A, n = 264) was compared with a 50% reduction of CNI and introduction of the mammalian target of rapamycin inhibitor Sirolimus (SIR) within 4-6 weeks after LT (group B, n = 261).
RESULTS
Median MELD at LT was low with 10 (7-15) (group A) and 11 (8-15) (group B) in the intention-to-treat approach. CNI dose and CNI trough were reduced by 20% and 8% (group A) versus 55% and 56% (group B) at 3 months posttransplantation. Renal function was preserved at 3 months after LT in the SIR arm (estimated glomerular filtration rate 74 [57-95] versus 67 [55-85] mL/min/1.73m2 P = 0.004) but was similarly impaired thereafter compared with group A. The per protocol analysis identified LT recipients in group B with concomitant early CNI minimization and SIR treatment ≥ year 1 with significantly superior estimated glomerular filtration rate and lowest rate of chronic kidney disease (≥stage 3) from year 1 onwards until study end. Competing risk factors for renal disease (arterial hypertension, fat metabolism disorder, and hyperglycemia) were not associated with worse kidney function.
CONCLUSIONS
Prevention of CNI nephrotoxicity by SIR-based early CNI minimization protects renal function only short-term after LT in the intention-to-treat analysis of this low MELD cohort. Yet, selected LT recipients compliant with early CNI minimization and SIR maintenance achieved better long-term renal outcomes compared with real-world practice.
Identifiants
pubmed: 31577671
doi: 10.1097/TP.0000000000002980
pii: 00007890-202005000-00022
doi:
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1018Références
Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506.Ann Surg1990212295–305discussion 306
Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.Lancet197921033–1036
Rush D. The impact of calcineurin inhibitors on graft survival.Transplant Rev (Orlando)20132793–95
Kahan BD. Cyclosporine.N Engl J Med19893211725–1738
O’Grady JG, Forbes A, Rolles K, et al. An analysis of cyclosporine efficacy and toxicity after liver transplantation.Transplantation198845575–579
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ.N Engl J Med2003349931–940
Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can’t live without.J Immunol20131915785–5791
Neuberger JM, Mamelok RD, Neuhaus P, et al.; ReSpECT Study GroupDelayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘respect’ study.Am J Transplant20099327–336
Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation–PROTECT.Am J Transplant2012121855–1865
Saliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial.Am J Transplant2017171843–1852
Teperman L, Moonka D, Sebastian A, et al.; Spare-the-Nephron Trial Liver Transplantation Study GroupCalcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.Liver Transpl201319675–689
Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs.Expert Rev Mol Med200021–23
Morales JM, Wramner L, Kreis H, et al.; Sirolimus European Renal Transplant Study GroupSirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.Am J Transplant20022436–442
Abdelmalek MF, Humar A, Stickel F, et al.; Sirolimus Liver Conversion Trial Study GroupSirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial.Am J Transplant201212694–705
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial.Transplantation2016100116–125
Geissler EK, Schnitzbauer AA, Schlitt HJ; SiLVER Study GroupThe authors’ reply.Transplantation2016100e44–e45
Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.BMC Cancer201010190
Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group.Ann Intern Med1999130461–470
Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney International Supplements201331–150
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med20043511296–1305
Ekberg H, Mamelok RD, Pearson TC, et al. The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study.Transplantation2009871360–1366
Colagiuri S. Optimal management of type 2 diabetes: the evidence.Diabetes Obes Metab201214Suppl 13–8
Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.Diabetes Obes Metab201214228–233
Rodríguez-Perálvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis.Am J Transplant2012122797–2814
Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.J Am Soc Nephrol2001121059–1071
Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The rapamune US study group.Lancet2000356194–202
Allen AM, Kim WR, Therneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation–a time-dependent analysis using measured glomerular filtration rate.J Hepatol201461286–292
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease.Hepatology200133464–470
Romano TG, Schmidtbauer I, Silva FM, et al. Role of MELD score and serum creatinine as prognostic tools for the development of acute kidney injury after liver transplantation.Plos One20138e64089
De Simone P, Nevens F, De Carlis L, et al.; H2304 Study GroupEverolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.Am J Transplant2012123008–3020
Schnitzbauer AA, Sothmann J, Baier L, et al. Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment: results of a pilot study (PATRON07).Transplantation2015992565–2575
Gatault P, Lebranchu Y. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Transplant Res20132Suppl 1S3
Leithead JA, Ferguson JW, Hayes PC. Modifiable patient factors are associated with the late decline in renal function following liver transplantation.Clin Transplant201226E316–E323
Levitsky J, O’Leary JG, Asrani S, et al. Protecting the kidney in liver transplant recipients: practice-based recommendations from the american society of transplantation liver and intestine community of practice.Am J Transplant2016162532–2544
Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population.BMC Nephrol20192093
Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy.Rheumatology (Oxford)201857suppl_1i47–i50
Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.Clin Transplant201630741–748
Londoño MC, Rimola A, O’Grady J, et al. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation.J Hepatol201359872–879